Dachaigh › Siostam Immune agus Galaran › Texas
Sgrùdaidhean clionaigeach Siostam Immune agus Galaran ann an Texas
Tha 14 sgrùdaidhean airson Siostam Immune agus Galaran a’ lorg phàirtichean aig làraichean ann an Texas.
Bailtean ann an Texas
Teacsa sgrùdaidh oifigeil (Beurla)
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- The Don and Sybil Harrington Cancer Center, Amarillo
- Audie L Murphy VA Hospital, San Antonio
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT04242095A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- The University of Texas - MD Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT07192471A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Houston
A’ fastadhÌre 2
Aoisean 18 gu 60 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07541287A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Sult 2026 · NCT06722235(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT04996875A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06948318Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT05826535Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Dallas Renal Group, Dallas
- Dallas Renal Group, Dallas
- Nephro Asso North Illinois Indiana, Houston
A’ fastadhÌre 3
Aoisean 18 gu 100 · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT06858319Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
- University of Texas at Austin, Austin
A’ fastadh
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT07759115A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 8, Southlake
A’ fastadhÌre 2
Aoisean 18 gu 74 · Gach gnè · Air ùrachadh 12 Lùna 2026 · NCT07037901A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
- Texas Children's Hospital, Houston
A’ fastadhÌre 2
Gach aois · Gach gnè · Air ùrachadh 2 Ògmh 2026 · NCT05787574A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- UT Southwestern Medical Center, Dept. of Dermatology, Dallas
- MD Anderson Texas Medical Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Cèit 2026 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- The University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Gibl 2026 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- St. David's South Austin Medical Center, Austin
- UT Southwestern Medical Center, Dallas
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Dùbh 2025 · NCT06619561Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.